Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy
Frontiers in Cardiovascular Medicine · 29.10.2025 · 12
DOI: 10.3389/fcvm.2025.1638380 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 29.10.2025. Verfasst von Ronald M Witteles und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine and Stanford Amyloid Center, Stanford University School of Medicine, Stanford, CA, United States. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Most patients with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) are diagnosed noninvasively, using nuclear imaging and monoclonal protein testing. However, concerns have been raised that some may receive an ATTRwt-CM diagnosis based on incomplete evaluations (not based on current consensus recommendations). Using a cohort of US Medicare Fee-for-Service patients, we aimed to examine the frequency and cadence of diagnostic testing for ATTRwt-CM.
Methods
In this retrospective observational cross-sectional study, administrative de-identified claims data from 2018 to 2022 were derived from patients aged ≥65 years who had at least one claim for ATTRwt-CM and heart failure or cardiomyopathy, and ≥2 years of continuous Medicare enrollment before the first ATTRwt-CM diagnosis. Patients with claims for any other form of amyloidosis, multiple myeloma, or plasma cell dyscrasias were excluded.
Results
Among 2,050 patients with ATTRwt-CM, mean (SD) age was 80.0 (6.9) years, and 75.5% were men. Annual new ATTRwt-CM diagnoses nearly tripled over the study period (2018, n = 198; 2022, n = 578). Technetium-99m pyrophosphate (PYP) scintigraphy use was performed in approximately half of diagnosed patients by the end of the study period (2018, 30%; 2022, 49%). Cardiac biopsy use declined from 14% in patients diagnosed in 2018 to 5% in those diagnosed in 2022. A small minority (14%) of patients underwent the recommended noninvasive diagnostic testing comprised of PYP scintigraphy and complete monoclonal protein testing.
Conclusions
Based on Medicare claims data, most patients diagnosed with ATTRwt-CM have not been diagnosed following consensus-recommended pathways.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine and Stanford Amyloid Center, Stanford University School of Medicine, Stanford, CA, United States.
- Pfizer, New York, NY, United States.
- Genesis Research Group, Hoboken, NJ, United States.
- Clarify Health Solutions, New York, NY, United States.
Zitieren
APA
Witteles, R. M., Chung, H., Dai, F., Gutierrez, C., Rava, A., Swarup, S., Ebrahim, A., & Pankratova, C. (2025). Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy. Frontiers in Cardiovascular Medicine, 12. https://doi.org/10.3389/fcvm.2025.1638380
Vancouver
Witteles RM, Chung H, Dai F, Gutierrez C, Rava A, Swarup S, et al. Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy. Frontiers in Cardiovascular Medicine. 2025;12. doi:10.3389/fcvm.2025.1638380
BibTeX
@article{Witteles2025,
author = {Witteles, Ronald M and Chung, Haechung and Dai, Feng and Gutierrez, Cynthia and Rava, Andrew and Swarup, Sameer and Ebrahim, Abbas and Pankratova, Cindi},
title = {Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy},
journal = {Frontiers in Cardiovascular Medicine},
year = {2025},
volume = {12},
doi = {10.3389/fcvm.2025.1638380}
}
EUVIMED